Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up – Still a Buy?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s share price gapped up prior to trading on Monday . The stock had previously closed at $44.63, but opened at $50.45. Supernus Pharmaceuticals shares last traded at $48.16, with a volume of 701,960 shares.

Supernus Pharmaceuticals News Roundup

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Supernus and Indivior agreed to a merger of equals that would create a diversified CNS-focused biopharmaceutical company with approximately $2.2 billion in combined annual revenue and an estimated $125 million in annual cost synergies. The combined company is expected to have approximately $888 million of adjusted EBITDA and greater scale for product development and acquisitions. Merger announcement
• Positive Sentiment: Second-quarter revenue rose 32% year over year to $219.1 million, led by growth products Qelbree, GOCOVRI, ONAPGO and ZURZUVAE collaboration revenue. Combined revenue from those growth products increased 52% to $175.7 million. Supernus also raised its 2026 revenue guidance to $860 million-$890 million and reiterated plans to seek FDA approval for a second ONAPGO supplier. Supernus second-quarter results
• Neutral Sentiment: The transaction is expected to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals. Supernus holders would receive 1.5401 Indivior shares for each SUPN share, while Indivior shareholders would own approximately 56.5% of the combined company. The fixed exchange ratio leaves SUPN investors exposed to changes in Indivior’s share price before closing.
• Negative Sentiment: Investors appear concerned that Indivior shareholders receive a $1 billion special dividend funded partly by $650 million of new debt, potentially shifting value away from Supernus holders and increasing leverage. Integration challenges and uncertainty over realizing the projected synergies add execution risk.
• Negative Sentiment: Although revenue grew, Supernus reported a $58.4 million GAAP net loss, including a $54.9 million non-cash impairment charge related to APOKYN. Full-year GAAP operating guidance now calls for a $20 million-$50 million loss, despite higher adjusted operating-earnings guidance. Supernus earnings and merger summary
• Negative Sentiment: Several shareholder-rights law firms announced investigations into whether the merger provides a fair price, creating potential litigation and transaction uncertainty. Separately, reported insider activity shows 17 sales and no purchases over the past six months.

Wall Street Analyst Weigh In

SUPN has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Cantor Fitzgerald raised their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Supernus Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $62.83.

Supernus Pharmaceuticals Trading Down 6.0%

The firm has a 50 day moving average of $46.13 and a 200-day moving average of $48.99. The company has a market cap of $2.51 billion, a P/E ratio of -84.80, a P/E/G ratio of 0.98 and a beta of 0.56.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of SUPN. Rockefeller Capital Management L.P. lifted its holdings in shares of Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 660 shares in the last quarter. Torren Management LLC bought a new stake in Supernus Pharmaceuticals in the 4th quarter valued at $49,000. EverSource Wealth Advisors LLC bought a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $51,000. Hantz Financial Services Inc. lifted its stake in Supernus Pharmaceuticals by 73.3% in the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 458 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter worth $55,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.